
CNTA Stock Forecast & Price Target
CNTA Analyst Ratings
Bulls say
Centessa Pharmaceuticals has shown promising advancements in its ORX750 development for Sleep Disorders, which has led to a reassessment of its revenue forecast and expectations for market penetration in the orexin agonist space. With a strong financial position, evident from approximately $405 million in cash reserves supporting operations into mid-2027, the company is well-positioned to capitalize on future data and developments in its pipeline. Moreover, the expected commercialization of its innovative products, including major market expansion potential within a narcolepsy market currently valued at around $2.5 billion, reflects a robust outlook for Centessa Pharmaceuticals.
Bears say
Centessa Pharmaceuticals PLC faces significant commercial, competitive, and reimbursement risks that could hamper the market potential of its pipeline assets. The company's analysis indicates that its current valuation reflects a minimal market penetration expectation, which disregards the growth potential of key assets like ORX750, further exacerbating the financial outlook. Additionally, potential delays in clinical trials, safety concerns, and uncertain patent protections contribute to a heightened risk profile that may lead to downward revisions in the company’s valuation.
This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.
CNTA Analyst Forecast & Price Prediction
Start investing in CNTA
Order type
Buy in
Order amount
Est. shares
0 shares